100P - 5-fluorouracil degradation rate as a predictive toxicity biomarker in early stage gastrointestinal cancer

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Anticancer agents
Gastrointestinal Cancers
Therapy
Biological Therapy
Presenter Michela Roberto
Citation Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363
Authors M. Roberto1, A. Romiti1, A. Botticelli2, F.R. Di Pietro1, L. Lionetto3, G. Gentile3, F. Mazzuca1, R. Falcone1, M. Occhipinti1, S. Macrini1, E. Anselmi1, A. Petremolo1, C.E. Onesti1, M. Simmaco4, P. Marchetti1
  • 1Clinical And Molecular Medicine, Azienda Ospedaliera St. Andrea - Roma, 00189 - Roma/IT
  • 2Medical Oncology, Azienda Ospedaliera St. Andrea - Roma, 00189 - Roma/IT
  • 3Nesmos, Sapienza University, Rome/IT
  • 4Nesmos, Sapienza University, 00187 - Rome/IT

Abstract

Background

Prediction and early management of severe toxicity might avoid both therapy's interruption and the benefit loss of adjuvant chemotherapy. However, predictive toxicity biomarkers are not yet available. The aim of this study was to investigate whether polymorphisms of different genes involved in fluoropyrimidine metabolism and 5-fluorouracil (5-FU) degradation rate were associated with clinical outcome of oral fluoropyrimidine-based adjuvant chemotherapy in patients with early stage GI cancer.

Methods

Genotyping of DPYD IVS14 IVS 14 + 1 G > A, MTHFR C677T and A1298C SNPs were performed by pyro-sequencing technology. PCR analysis was used for genotyping TYMS-TSER. Using PBMC cells, we also evaluated the 5-FU degradation rate, which determines the amount of drug consumed by cells in a time unit. Patients were categorized in two groups according to their value of 5-FU degradation rate: below the 5th centile (poor metabolism - PM) or above the 95th centile (ultra-rapid metabolism - UM) and within 5-95th centile (0.85-2.2 ng/ml/106 cells/min).

Results

One hundred forty-two patients with early stage colon (39%), rectal (28%), stomach (20%) and pancreatic (13%) cancer, treated with 5FU-based adjuvant monochemotherapy, were included in this retrospective analysis. Forty-three per cent of patients had a lymphnode-positive disease, and 37% received concomitant radiotherapy. Most of patients had an ECOG PS = 0-1. Seventy-four and 20% of the patients suffered from at least one G1-4 and G3-4 adverse events (12 hematologic, 24 GI, 12 HFS), respectively. Sixteen (11%) patients resulted abnormal 5-FU metabolizers. At a multivariate logistic regression analysis, an altered 5-FU degradation rate (2.10) resulted significantly associated with both G1-4 hematologic (OR = 2.99, 95% CI 0.98-9.12, P = 0.05) and all grade 3-4 adverse events (OR = 4.39, 95% CI 1.40-13.80, P = 0.01). No correlation was reported between toxicity and each tested gene polymorphism.

Conclusions

Our study showed a statistically significant association between 5-FU degradation rate and both G1-4 hematologic and all G3-4 toxicities. Therefore, the 5FU-degradation rate may be considered as a putative, predictive biomarker of fluoropyrimidine-related toxicity.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

Self-funded

Disclosure

All authors have declared no conflicts of interest.